A pair of separate launches highlight rising interest in modality-first gene delivery and platform integration. In one case, SonoThera’s funding accelerates its pathway into clinical evaluation using microbubble activation. In the diagnostics space, coverage decisions like CMS’s ColoSense approval support expansion of RNA-based screening. Together, the moves illustrate how payor reimbursement and capital formation are converging to reduce adoption friction for new biotech modalities, from gene delivery to multiplexed molecular diagnostics. While both developments are early relative to full commercial outcomes, the operational steps—clinical initiation readiness and coverage frameworks—are immediate gatekeepers for scale.